SpectraCell Labs Debuts PCR-Based apoE Test

By Kirell Lakhman

SpectraCell Laboratories has begun offering a PCR-based apolipoprotein E genotyping service that uses the marker for cholesterol and triglyceride metabolism to gauge an individual's risk for cardiovascular disease and determine treatment.

The test costs $150 and is "typically covered by insurance," the CLIA lab said in a statement last week.

ApoE is a protein that helps determine how well the body can clear cholesterol from cells and how efficiently the liver excretes it.

The six possible apoE genotypes that a person can carry — e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, and e4/e4 — will determine how effectively certain therapies, such as statins, will lower their risk of heart disease.

According to Houston-based SpectraCell, its apoE assay, combined with its lipoprotein particle numbers test, can help physicians suggest lifestyle and medication options.

"Unlike traditional cholesterol tests, [the] LPP assay] directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk," SpectraCell said.

According to Lab Tests Online, apoE testing, which is also sometimes used as an adjunct test to help diagnose probable late-onset Alzheimer’s disease in symptomatic adults, "is not widely used and its clinical usefulness is still being researched."